|
Pathogens Interest1 #715325
| |
+Citations (3) - CitationsAjouter une citationList by: CiterankMapLink[1] The role of mucosal barriers in disease progression and transmission
En citant: Nicole A. Bustos, Katharina Ribbeck, Caroline E. Wagner Publication date: 12 August 2023 Publication info: Advanced Drug Delivery Reviews, Volume 200, 2023,
115008, ISSN 0169-409X CitĂ© par: David Price 1:22 AM 13 December 2023 GMT Citerank: (2) 679762Caroline E WagnerCaroline Wagner is an Assistant Professor in the Department of the Bioengineering at McGill University.10019D3ABAB, 701020CANMOD â PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1016/j.addr.2023.115008
| Extrait - [Advanced Drug Delivery Reviews, 12 August 2023.]
Mucus is a biological hydrogel that coats and protects all non-keratinized wet epithelial surfaces. Mucins, the primary structural components of mucus, are critical components of the gel layer that protect against invading pathogens. For communicable diseases, pathogen-mucin interactions contribute to the pathogenâs fate and the potential for disease progression in-host, as well as the potential for onward transmission. We begin by reviewing in-host mucus filtering mechanisms, including size filtering and interaction filtering, which regulate the permeability of mucus barriers to all molecules including pathogens. Next, we discuss the role of mucins in communicable diseases at the point of transmission (i.e. how the encapsulation of pathogens in emitted mucosal droplets externally to hosts may modulate pathogen infectivity and viability). Overall, mucosal barriers modulate both host susceptibility as well as the dynamics of population-level disease transmission. The study of mucins and their use in models and experimental systems are therefore crucial for understanding the mechanistic biophysical principles underlying disease transmission and the early stages of host infection. |
Link[2] Intramammary and systemic use of antimicrobials and their association with resistance in generic Escherichia coli recovered from fecal samples from Canadian dairy herds: A cross-sectional study
En citant: Mariana Fonseca, Luke C. Heider, Henrik Stryhn, J.Trenton McClure, David LĂ©ger, Daniella Rizzo, Landon Warder, Simon Dufour, Jean-Philippe Roy, David F. Kelton, David Renaud, Herman W. Barkema, Javier Sanchez Publication date: 30 May 2023 Publication info: Preventive Veterinary Medicine, Volume 216, 2023, 105948, ISSN 0167-5877, CitĂ© par: David Price 0:48 AM 14 December 2023 GMT Citerank: (4) 679809Javier SanchezProfessor of Epidemiology at University of Prince Edward Island.10019D3ABAB, 701020CANMOD â PublicationsPublications by CANMOD Members144B5ACA0, 703961Zoonosis859FDEF6, 704017Antimicrobial resistance859FDEF6 URL: DOI: https://doi.org/10.1016/j.prevetmed.2023.105948
| Extrait - [Preventive Veterinary Medicine, 30 May 2023]
Antimicrobial resistance (AMR) in animals, including dairy cattle, is a significant concern for animal and public health worldwide. In this study, we used data collected through the Canadian Dairy Network for Antimicrobial Stewardship and Resistance (CaDNetASR) to: (1) describe the proportions of AMR in fecal E. coli, and (2) investigate the relationship between antimicrobial use (AMU) (intramammary and systemic routes, while accounting for confounding by other variables) and AMR/multidrug resistance (MDR â resistance to â„ 3 antimicrobial classes) in fecal E. coli from Canadian dairy farms. We hypothesized that an increase of the AMU was associated with an increase in AMR in E. coli isolates. A total of 140 dairy farms across five provinces in Canada were included in the study. Fecal samples from pre-weaned calves, post-weaned heifers, lactating cows, and farm manure storage were cultured, and E. coli isolates were identified using MALDI-TOF MS. The minimum inhibitory concentrations (MIC) to 14 antimicrobials were evaluated using a microbroth dilution methodology. AMU was quantified in Defined Course Dose (DCD - the dose for a standardized complete treatment course on a standard size animal) and converted to a rate indicator - DCD/100 animal-years. Of 1134 fecal samples collected, the proportion of samples positive for E. coli in 2019 and 2020 was 97.1% (544/560) and 94.4% (542/574), respectively. Overall, 24.5% (266/1086) of the E. coli isolates were resistant to at least one antimicrobial. Resistance towards tetracycline was commonly observed (20.7%), whereas resistance to third-generation cephalosporins, fluoroquinolones, and carbapenems was found in 2.2%, 1.4%, and 0.1% of E. coli isolates, respectively. E. coli isolates resistant to two or â„ 3 antimicrobial classes (MDR) was 2.7% and 15%, respectively. Two multilevel models were built to explore risk factors associated with AMR with AMU being the main exposure. Systemic AMU was associated with increased E. coli resistance. For an increase in systemic AMU equivalent to its IQR, the odds of resistance to any antimicrobial in the model increased by 18%. Fecal samples from calves had higher odds of being resistant to any antimicrobial when compared to other production ages and farm manure storage. The samples collected in 2020 were less likely to be resistant when compared to samples collected in 2019. Compared to previous studies in dairy cattle in North America, AMR in E. coli was lower. |
Link[3] Longitudinal genomic surveillance of multidrug-resistant Escherichia coli carriage in critical care patients
En citant: Mira El Chaar, Yaralynn Khoury, Gavin M. Douglas, Samir El Kazzi, Tamima Jisr, Shatha Soussi, Georgi Merhi, Rima A. Moghnieh, B. Jesse Shapiro Publication date: 3 January 2024 Publication info: Clinical Microbiology, 3 January 2024 CitĂ© par: David Price 9:41 PM 4 March 2024 GMT Citerank: (3) 679756Jesse ShapiroJesse Shapiro is an Associate Professor in the Faculty of Medicine and Health Sciences at McGill University. Jesseâs research uses genomics to understand the ecology and evolution of microbes, ranging from freshwater bacterioplankton to the human gut microbiome. His work has helped elucidate the origins of bacterial species, leading to a more unified species concept across domains of life, and has developed genome-wide association study (GWAS) methods tailored for bacteria.10019D3ABAB, 701020CANMOD â PublicationsPublications by CANMOD Members144B5ACA0, 708734Genomics859FDEF6 URL: DOI: https://doi.org/10.1128/spectrum.03128-23
| Extrait - [Clinical Microbiology, 3 January 2024]
Colonization with multidrug-resistant Escherichia coli strains causes a substantial health burden in hospitalized patients. We performed a longitudinal genomics study to investigate the colonization of resistant E. coli strains in critically ill patients and to identify evolutionary changes and strain replacement events within patients. Patients were admitted to the intensive care unit and hematology wards at a major hospital in Lebanon. Perianal swabs were collected from participants on admission and during hospitalization, which were screened for extended-spectrum beta-lactamases and carbapenem-resistant Enterobacterales. We performed whole-genome sequencing and analysis on E. coli strains isolated from patients at multiple time points. The E. coli isolates were genetically diverse, with 11 sequence types (STs) identified among 22 isolates sequenced. Five patients were colonized by E. coli sequence type 131 (ST131)-encoding CTX-M-27, an emerging clone not previously observed in clinical samples from Lebanon. Among the eight patients whose resident E. coli strains were tracked over time, five harbored the same E. coli strain with relatively few mutations over the 5 to 10 days of hospitalization. The other three patients were colonized by different E. coli strains over time. Our study provides evidence of strain diversity within patients during their hospitalization. While strains varied in their antimicrobial resistance profiles, the number of resistance genes did not increase over time. We also show that ST131-encoding CTX-M-27, which appears to be emerging as a globally important multidrug-resistant E. coli strain, is also prevalent among critical care patients and deserves further monitoring. |
|
|